This Program will be funded at $100,000 annually, and generally given with the intention of funding awardees for two years at $50,000 each year. As with pilot projects, plans change and grants may become available for one year of funding. The purpose of the Awards is to attract basic, translational and clinical investigators into breast cancer research, to provide them with information about human breast cancer, mentor them in their chosen career pathways, and integrate the recipients into the translational mission of the SPORE. A process of nomination, application and committee review will generally be used to distribute the Awards. On occasion, the Principal investigator my recommend appointment (for instance to a one-year slot, or if funds become available off-schedule). The purpose of the nominating process (senior faculty recommending junior faculty) is to assure the day-to-day presence of a mentor for the award recipients. However, more senior faculty are eligible to apply if they are not members of the Breast Program in the DF/HCC, but seek association with the SPORE and have a promising project that would benefit from SPORE membership. In practice, the typical applicant is junior faculty member with a strong program of research, a secure position in a mentoring environment, and the need for funding as a bridge to independence. Award recipients should attend SPORE functions, use SPORE Cores, and will meet with Dr. Iglehart on a regular basis.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Kabraji, Sheheryar; Ni, Jing; Lin, Nancy U et al. (2018) Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res 24:1795-1804
Punglia, Rinaa S; Jiang, Wei; Lipsitz, Stuart R et al. (2018) Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat 167:751-759
Liu, Hui; Murphy, Charles J; Karreth, Florian A et al. (2018) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov 8:354-369
Asdourian, Maria S; Swaroop, Meyha N; Sayegh, Hoda E et al. (2017) Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery. J Clin Oncol 35:3934-3941
Sun, Fangdi; Skolny, Melissa N; Swaroop, Meyha N et al. (2016) The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema. Breast Cancer Res Treat 157:229-240
Ferguson, Chantal M; Swaroop, Meyha N; Horick, Nora et al. (2016) Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer. J Clin Oncol 34:691-8
Miller, Cynthia L; Colwell, Amy S; Horick, Nora et al. (2016) Immediate Implant Reconstruction Is Associated With a Reduced Risk of Lymphedema Compared to Mastectomy Alone: A Prospective Cohort Study. Ann Surg 263:399-405
Sherr, Charles J; Beach, David; Shapiro, Geoffrey I (2016) Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov 6:353-67
Asdourian, Maria S; Skolny, Melissa N; Brunelle, Cheryl et al. (2016) Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis. Lancet Oncol 17:e392-405
Kochupurakkal, Bose S; Iglehart, J Dirk (2016) Identification of genes responsible for RelA-dependent proliferation arrest in human mammary epithelial cells conditionally expressing RelA. Genom Data 7:92-3

Showing the most recent 10 out of 291 publications